BACKGROUND: Vaccination has proven to be effective in preventing SARS-CoV-2 transmission and severe disease courses. However, immunocompromised patients have not been included in clinical trials and real-world clinical data point to an attenuated immune response to SARS-CoV-2 vaccines among patients with multiple sclerosis (MS) receiving immunomodulatory therapies. METHODS: We performed a retrospective study including 59 ocrelizumab (OCR)-treated patients with MS who received SARS-CoV-2 vaccination. Anti-SARS-CoV-2-antibody titres, routine blood parameters and peripheral immune cell profiles were measured prior to the first (baseline) and at a median of 4 weeks after the second vaccine dose (follow-up). Moreover, the SARS-CoV-2-specific T cell response and peripheral B cell subsets were analysed at follow-up. Finally, vaccination-related adverse events were assessed. RESULTS: After vaccination, we found anti-SARS-CoV-2(S) antibodies in 27.1% and a SARS-CoV-2-specific T cell response in 92.7% of MS cases. T cell-mediated interferon (IFN)-γ release was more pronounced in patients without anti-SARS-CoV-2(S) antibodies. Antibody titres positively correlated with peripheral B cell counts, time since last infusion and total IgM levels. They negatively correlated with the number of previous infusion cycles. Peripheral plasma cells were increased in antibody-positive patients. A positive correlation between T cell response and peripheral lymphocyte counts was observed. Moreover, IFN-γ release was negatively correlated with the time since the last infusion. CONCLUSION: In OCR-treated patients with MS, the humoral immune response to SARS-CoV-2 vaccination is attenuated while the T cell response is preserved. However, it is still unclear whether T or B cell-mediated immunity is required for effective clinical protection. Nonetheless, given the long-lasting clinical effects of OCR, monitoring of peripheral B cell counts could facilitate individualised treatment regimens and might be used to identify the optimal time to vaccinate.

Brain and Mind Centre The University of Sydney Camperdown New South Wales Australia

Clinical Immunological Laboratory Prof Dr med Winfried Stöcker Lübeck Germany

Department of Neurology Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Palacky University Olomouc Czech Republic

Institute of Molecular Medicine 3 Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany

Sydney Neuroimaging Analysis Centre The University of Sydney Camperdown New South Wales Australia

Zobrazit více v PubMed

Polack FP, Thomas SJ, Kitchin N, et al. . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603–15. 10.1056/NEJMoa2034577 PubMed DOI PMC

Baden LR, El Sahly HM, Essink B, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403–16. 10.1056/NEJMoa2035389 PubMed DOI PMC

Huang Y, Yang C, Xu X-F, et al. . Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 2020;41:1141–9. 10.1038/s41401-020-0485-4 PubMed DOI PMC

Wu Q, Dudley MZ, Chen X, et al. . Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med 2021;19:173. 10.1186/s12916-021-02059-5 PubMed DOI PMC

Walsh EE, Frenck RW, Falsey AR, et al. . Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020;383:2439–50. 10.1056/NEJMoa2027906 PubMed DOI PMC

European Medicines Agency . Ocrevus - Summary of product characteristics [Internet]. Available: https://ec.europa.eu/health/documents/community-register/2021/20210111150165/anx_150165_en.pdf [Accessed 15 Jun 2021].

Roche H-L. New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis [Internet]. Available: https://www.roche.com/media/releases/med-cor-2021-04-16.htm [Accessed 06 Oct 2021].

Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther 2013;15 Suppl 1:S3. 10.1186/ar3908 PubMed DOI PMC

Chen Q, Yuan S, Sun H, et al. . CD3+CD20+ T cells and their roles in human diseases. Hum Immunol 2019;80:191–4. 10.1016/j.humimm.2019.01.001 PubMed DOI

Shen P, Fillatreau S. Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol 2015;15:441–51. 10.1038/nri3857 PubMed DOI

Nutt SL, Hodgkin PD, Tarlinton DM, et al. . The generation of antibody-secreting plasma cells. Nat Rev Immunol 2015;15:160–71. 10.1038/nri3795 PubMed DOI

Apostolidis SA, Kakara M, Painter MM, et al. . Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 2021;27:1990–2001. 10.1038/s41591-021-01507-2 PubMed DOI PMC

Monschein T, Hartung H-P, Zrzavy T, et al. . Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. J Neurol Neurosurg Psychiatry 2021;92:1033–43. 10.1136/jnnp-2021-326839 PubMed DOI PMC

Brill L, Rechtman A, Zveik O, et al. . Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with Ocrelizumab. JAMA Neurol 2021;78:1510. 10.1001/jamaneurol.2021.3599 PubMed DOI PMC

Disanto G, Sacco R, Bernasconi E, et al. . Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA Neurol 2021;78:1529. 10.1001/jamaneurol.2021.3609 PubMed DOI PMC

Hauser SL, Bar-Or A, Comi G, et al. . Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221–34. 10.1056/NEJMoa1601277 PubMed DOI

Montalban X, Hauser SL, Kappos L, et al. . Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209–20. 10.1056/NEJMoa1606468 PubMed DOI

Ren L, Zhang L, Chang D, et al. . The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol 2020;3:780. 10.1038/s42003-020-01526-8 PubMed DOI PMC

Luna G, Alping P, Burman J, et al. . Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 2020;77:184–91. 10.1001/jamaneurol.2019.3365 PubMed DOI PMC

Corey L, Beyrer C, Cohen MS, et al. . SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med 2021;385:562–6. 10.1056/NEJMsb2104756 PubMed DOI PMC

Ferguson J, Murugesan K, Banaei N. Interferon-Gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report. Int J Infect Dis 2021. PubMed PMC

Thompson AJ, Banwell BL, Barkhof F, et al. . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73. 10.1016/S1474-4422(17)30470-2 PubMed DOI

Rolfes L, Pawlitzki M, Pfeuffer S, et al. . Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm 2021;8. 10.1212/NXI.0000000000001035. [Epub ahead of print: 14 Jul 2021]. PubMed DOI PMC

Bayram A, Demirbakan H, Günel Karadeniz P, et al. . Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol 2021;93:5560–7. 10.1002/jmv.27098 PubMed DOI PMC

Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J Clin Invest 2021;131. 10.1172/JCI149335. [Epub ahead of print: 17 May 2021]. PubMed DOI PMC

Sormani MP, De Rossi N, Schiavetti I, et al. . Disease-Modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 2021;89:780–9. 10.1002/ana.26028 PubMed DOI PMC

Sahraian MA, Azimi A, Navardi S, et al. . Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord 2020;46:102472. 10.1016/j.msard.2020.102472 PubMed DOI PMC

Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 2020;43:102195. 10.1016/j.msard.2020.102195 PubMed DOI PMC

Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, et al. . Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord 2020;42:102185. 10.1016/j.msard.2020.102185 PubMed DOI PMC

Parrotta E, Kister I, Charvet L, et al. . COVID-19 outcomes in MS: observational study of early experience from NYU multiple sclerosis comprehensive care center. Neurol Neuroimmunol Neuroinflamm 2020;7. 10.1212/NXI.0000000000000835. [Epub ahead of print: 09 Jul 2020]. PubMed DOI PMC

Louapre C, Collongues N, Stankoff B, et al. . Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 2020;77:1079–88. 10.1001/jamaneurol.2020.2581 PubMed DOI PMC

Tortorella C, Aiello A, Gasperini C, et al. . Humoral- and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies. Neurology 2022;98:e541–54. 10.1212/WNL.0000000000013108 PubMed DOI PMC

Achiron A, Mandel M, Dreyer-Alster S, et al. . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 2021;14:17562864211012836. 10.1177/17562864211012835 PubMed DOI PMC

Sanz I, Wei C, Jenks SA, et al. . Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front Immunol 2019;10:2458. 10.3389/fimmu.2019.02458 PubMed DOI PMC

Roll P, Palanichamy A, Kneitz C, et al. . Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377–86. 10.1002/art.22019 PubMed DOI

Bittner S, Ruck T, Wiendl H, et al. . Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord 2017;10:51–66. 10.1177/1756285616666741 PubMed DOI PMC

Le Bert N, Tan AT, Kunasegaran K, et al. . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020;584:457–62. 10.1038/s41586-020-2550-z PubMed DOI

Cao W-C, Liu W, Zhang P-H, et al. . Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med 2007;357:1162–3. 10.1056/NEJMc070348 PubMed DOI

Ng O-W, Chia A, Tan AT, et al. . Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine 2016;34:2008–14. 10.1016/j.vaccine.2016.02.063 PubMed DOI PMC

Wang F, Hou H, Luo Y, et al. . The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight 2020;5. 10.1172/jci.insight.137799. [Epub ahead of print: 21 May 2020]. PubMed DOI PMC

Heming M, Li X, Räuber S, et al. . Neurological manifestations of COVID-19 feature T cell exhaustion and dedifferentiated monocytes in cerebrospinal fluid. Immunity 2021;54:164–75. 10.1016/j.immuni.2020.12.011 PubMed DOI PMC

Ngai P, McCormick S, Small C, et al. . Gamma interferon responses of CD4 and CD8 T-cell subsets are quantitatively different and independent of each other during pulmonary Mycobacterium bovis BCG infection. Infect Immun 2007;75:2244–52. 10.1128/IAI.00024-07 PubMed DOI PMC

Gutierrez L, Beckford J, Alachkar H. Deciphering the TCR repertoire to solve the COVID-19 mystery. Trends Pharmacol Sci 2020;41:518–30. 10.1016/j.tips.2020.06.001 PubMed DOI PMC

Lotan I, Wilf-Yarkoni A, Friedman Y, et al. . Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel. Eur J Neurol 2021;28:3742–8. 10.1111/ene.15028 PubMed DOI PMC

Di Filippo M, Cordioli C, Malucchi S. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatr 2021. PubMed

Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis

B cell targeted therapies in inflammatory autoimmune disease of the central nervous system

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

Vaccination and immunotherapies in neuroimmunological diseases